Company Description: GelMEDIX is a seed-stage, Harvard/UCLA founded, cell therapy company focused on overcoming the fundamental challenges of current retinal cell therapy technologies to create vision restoring products for patients. Current retinal cell therapies, in particular retinal pigment epithelial (RPE) cell therapies formulated in saline for geographic atrophy, suffer from poor cell localization leading to epiretinal membrane formation, poor cell viability, and poor monolayer formation, which ultimately leads to suboptimal vision restoration. GelMEDIX's proprietary injectable, in situ forming hydrogel technology overcomes these challenges and has been shown in vivo to improve cell localization and phenotype post-injection. GelMEDIX is raising a Series A financing to bring its lead RPE cell therapy program through clinical proof-of-concept and to expand its pipeline into other ocular cell therapies. GelMEDIX is led by an experienced team of scientists, physicians, entrepreneurs, and investors.